Disease Focus: Amyotrophic Lateral Sclerosis
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons
One of the main objectives of stem cell biology is to create physiologically relevant cell types that can be used to either facilitate the study of or directly treat human disease. Tremendous progress towards these goals has been made in the area of motor neuron disease and spinal cord injury through the findings that motor […]
Facebook Live: Stem Cells and ALS
This Facebook Live event, “Ask the Stem Cell Team about ALS”, aired on July 31st, 2018 and featured a conversation between Drs. Clive Svendsen, Robert Baloh from Cedars-Sinai, Dr. Ralph Kern, the Chief Operating Officer and Chief Medical Officer of Brainstorm Therapeutics, and CIRM Senior Science Officer Dr. Lila Collins. Make sure to “like” CIRM’s […]
Stem Cells in Your Face: Treating ALS with a Disease in a Dish
To a stem cell scientist, “Disease in a Dish” describes a powerful way to study human disease in the lab using a Nobel Prize winning technique. But to a non-scientist it sounds more like a scene from some disgusting sci-fi horror cooking show. Our latest video takes a lighthearted approach to help clear up any […]
Google Hangout: Progress Toward Stem Cell Therapies for ALS
On July 3rd, CIRM hosted a Google Hangout to discuss progress toward stem cell therapies for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. Dr. Clive Svendsen, a CIRM grantee and director of the Cedar Sinai Regenerative Medicine Institute, joined the hangout to describe his efforts to bring a stem cell based ALS […]
Webinar: Injecting Neural Stem Cells into ALS Patients: Results of a Phase 1 Trial | Jonathan Glass
Title: Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients Speaker: Jonathan D. Glass, M.D. Professor, Neurology and Pathology, Emory University School of Medicine Presented April 15, 2013 This presentation was part of the webinar event, “Clinical Trials: Moving Stem Cell based Therapies to […]
$18 Million ALS Research Grant for Stem Cell Therapy Applauded by ALS Advocates
On July 26th 2012, the governing board of California’s Stem Cell Agency approved an $18 million Disease Team research grant that aims to bring a stem cell-based ALS treatment to clinical trials. The project team is led by Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute and chair of the California ALS Research […]
Lou Gehrig’s Disease (ALS): Progress and Promise in Stem Cell Research
CIRM has funded the ALS Disease Team led by scientists at who aim to bring a human embryonic stem cell based ALS therapy to clinical trials within four years. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, is a progressive motor neuron disorder. Most people with ALS die within 3 to 5 years […]
Spotlight on Disease Team Awards – ALS: Introduction
Spotlight on ALS: Introduction Robert Klein, J.D. and Larry Goldstein, Ph.D. spoke at the “Spotlight on Disease Team Awards: ALS,” an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Klein and Goldstein introduced the CIRM ALS Disease Team. Klein is chair of the CIRM Governing Board. Goldstein is the principle […]
Spotlight on Disease Team Awards – ALS: Larry Goldstein
Spotlight on ALS: Larry Goldstein Introduction to ALS: our team and our approach Larry Goldstein, Ph.D. spoke at the “Spotlight on Disease Team Awards: ALS,” an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Goldstein is the principle investigator of the CIRM ALS Disease Team and director of the UC […]
Spotlight on Disease Team Awards – ALS: Don Cleveland
Spotlight on ALS: Don Cleveland Scientific background and rationale for our approach Don Cleveland, Ph.D. spoke at the “Spotlight on Disease Team Awards: ALS,” an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Goldstein is a co-principle investigator of the CIRM ALS Disease Team and member of The Ludwig Institute. […]